Starpharma Interim Report and Half-Year Financial Results

26 February 2018

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its interim report and financial results for the half-year ended 31 December 2017.

Financial Summary

  • Reported loss of $6.2M (Dec 2016: $9.0M); and
  • Cash position at 31 December 2017 of $49.9M (June 2017: $61.2M) and excludes the $3.7M FY17 R&D tax incentive and US$2.4M FDA refunds subsequently received.

Read more

© Starpharma Holdings Limited 2017